BsAb vs CAR-T toxicity
| Agent . | CRS rate . | Neurotoxicity rate . | Treatment discontinuation due to AEs . | Grade 3+ infections . | Tocilizumab required . | ||
|---|---|---|---|---|---|---|---|
| Any grade . | Grade 3+ . | Any grade . | Grade 3+ . | ||||
| Mosunetuzumab | 44% | 2% | 5% | 2% | 4% | 13% | 8% |
| Epcoritamaba | 49% | 0% | 0% | 0% | 19% | NR | 12% |
| Odronextamabb | 57% | 1% | 1% | 0% | 16% | 41% | 17% |
| Axicabtagene-ciloleucel | 78% | 6% | 56% | 15% | NA | 15% | 50% |
| Tisagenlecleucel | 49% | 0% | 4% | 1% | NA | 9% | 34% |
| Lisocabtagene-maraleucelc | 58% | 1% | 15% | 2% | NA | 5% | 25% |
| Agent . | CRS rate . | Neurotoxicity rate . | Treatment discontinuation due to AEs . | Grade 3+ infections . | Tocilizumab required . | ||
|---|---|---|---|---|---|---|---|
| Any grade . | Grade 3+ . | Any grade . | Grade 3+ . | ||||
| Mosunetuzumab | 44% | 2% | 5% | 2% | 4% | 13% | 8% |
| Epcoritamaba | 49% | 0% | 0% | 0% | 19% | NR | 12% |
| Odronextamabb | 57% | 1% | 1% | 0% | 16% | 41% | 17% |
| Axicabtagene-ciloleucel | 78% | 6% | 56% | 15% | NA | 15% | 50% |
| Tisagenlecleucel | 49% | 0% | 4% | 1% | NA | 9% | 34% |
| Lisocabtagene-maraleucelc | 58% | 1% | 15% | 2% | NA | 5% | 25% |
EPCORE NHL-1 FL study: N = 128 for efficacy and safety except for CRS and ICANS (N = 86 optimization cohort).
ELM-2 study: N = 128 for efficacy and safety except for CRS and ICANS (N = 60 optimization cohort).
TRANSCEND FL study: third-line or beyond FL for efficacy (N = 107), second-line or beyond FL for safety (N = 130).
NA, not applicable; NR, not reported.